Trials Today

Subprotocol A, B, and C - Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years). - Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing. - Homozygous MTAP-deletion - Able to swallow and retain PO administered study treatment. - Disease measurable as defined by RECIST v1.1. Subprotocol A - Histologically or cytologically confirmed diagnosis of NSCLC. Arm A (AMG 193 + carboplatin + paclitaxel + pembrolizumab): - Predominantly squamous histology. Arm B (AMG 193 + carboplatin + pemetrexed + pembrolizumab): - Predominantly non-squamous histology. Arm C (AMG 193 + pembrolizumab): - PD-L1 positive. Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation. Subprotocol C - Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases. - Brain lesion meeting RANO-BM criteria for measurable disease.

Subprotocol A, B, and C - Cardiovascular and pulmonary exclusion criteria as defined in the protocol. - Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis). - History of solid organ transplant. - Major surgery within 28 days of first dose of AMG 193. - Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor. - Radiation therapy within 28 days of first dose. Subprotocol A - Autoimmune disease or immunodeficiency disease as defined in the protocol'